Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 63, Issue 7, 2007, Pages 647-656

  Munafo, Alain ^a   Priestley, Anthony ^b   Nestorov, Ivan ^c   Visich, Jennifer ^c   Rogge, Mark ^c  

^a MERCK SERONO S A   (Switzerland)

^b LCG Bioscience   (United Kingdom)

^c ZYMOGENETICS INC   (United States)

Author keywords

APRIL; Atacicept; BLyS; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ACETYLSALICYLIC ACID; ATACICEPT; HYBRID PROTEIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PARACETAMOL; PLACEBO; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; BACKACHE; BLOOD ANALYSIS; BLOOD CHEMISTRY; BLOOD CLOTTING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; COUGHING; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; EYELID EDEMA; FLU LIKE SYNDROME; HUMAN; HUMAN EXPERIMENT; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; JOINT INJURY; LYMPHOCYTE COUNT; MALE; MOUTH ULCER; NAUSEA; NORMAL HUMAN; NOSE CONGESTION; PERIANAL ABSCESS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SORE THROAT; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER ABDOMINAL PAIN; URINALYSIS; VIROLOGY; VITAL SIGN; VOMITING;

ADOLESCENT; ADULT; AREA UNDER CURVE; B-CELL ACTIVATING FACTOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 34250365790     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-007-0311-7     Document Type: Article

References (15)

1. Bossen C, Schneider P (2006) BAFF, APRIL and their receptors: Structure, function and signaling. Semin Immunol 18:263-275
2. Cheema GS, Roschke V, Hilbert DM, Stohl W (2001) Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 44:1313-1319
3. Dillon SR, Gross JA, Ansell SM, Novak AJ (2006) An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 5:235-246
4. Groom J, Kalled SL, Cutler AH, Olson C, Woodcock SA, Schneider P, Tschopp J, Cachero TG, Batten M, Wheway J, Mauri D, Cavill D, Gordon TP, Mackay CR, Mackay F (2002) Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. J Clin Invest 109:59-68
5. Gross JA, Dillon SR, Mudri S, Johnston J, Littau A, Roque R, Rixon M, Schou O, Foley KP, Haugen H, McMillen S, Waggie K, Schreckhise RW, Shoemaker K, Vu T, Moore M, Grossman A, Clegg CH (2001) TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS. Immunity 15:289-302
6. Gross JA, Johnston J, Mudri S, Enselman R, Dillon SR, Madden K, Xu W, Parrish-Novak J, Foster D, Lofton-Day C, Moore M, Littau A, Grossman A, Haugen H, Foley K, Blumberg H, Harrison K, Kindsvogel W, Clegg CH (2000) TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 404:995-999
7. Hahne M, Kataoka T, Schroter M, Hofmann K, Irmler M, Bodmer JL, Schneider P, Bornand T, Holler N, French LE, Sordat B, Rimoldi D, Tschopp J (1998) APRIL, a new ligand of the tumor necrosis factor family, stimulates tumor cell growth. J Exp Med 188:1185-1190
8. Hendriks J, Planelles L, de Jong-Odding J, Hardenberg G, Pals ST, Hahne M, Spaargaren M, Medema JP (2005) Heparan sulfate proteoglycan binding promotes APRIL-induced tumor cell proliferation. Cell Death Differ 12:637-648
9. Huntington ND, Tomioka R, Clavarino C, Chow AM, Linares D, Mana P, Rossjohn J, Cachero TG, Qian F, Kalled SL, Bernard CC, Reid HH (2006) A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol 18:1473-1485
10. Ingold K, Zumsteg A, Tardivel A, Huard B, Steiner QG, Cachero TG, Qiang F, Gorelik L, Kalled SL, Acha-Orbea H, Rennert PD, Tschopp J, Schneider P (2005) Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 201:1375-1383
11. Mackay F, Leung H (2006) The role of the BAFF/APRIL system on T cell function. Semin Immunol 18:284-289
12. Moore PA, Belvedere O, Orr A, Pieri K, LaFleur DW, Feng P, Soppet D, Charters M, Gentz R, Parmelee D, Li Y, Galperina O, Giri J, Roschke V, Nardelli B, Carrell J, Sosnovtseva S, Greenfield W, Ruben SM, Olsen HS, Fikes J, Hilbert DM (1999) BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator. Science 285:260-263
13. Schneider P, MacKay F, Steiner V, Hofmann K, Bodmer JL, Holler N, Ambrose C, Lawton P, Bixler S, Acha-Orbea H, Valmori D, Romero P, Werner-Favre C, Zubler RH, Browning JL, Tschopp J (1999) BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 189:1747-1756
14. Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, Migone TS, Hilbert DM, Stohl W (2003) Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis. Arthritis Rheum 48:982-992
15. Zhang J, Roschke V, Baker KP, Wang Z, Alarcon GS, Fessler BJ, Bastian H, Kimberly RP, Zhou T (2001) Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 166:6-10